Refractory Bullous Pemphigoid Successfully Treated with Reslizumab: A Possible Novel Therapeutic Modality
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Bullous pemphigoid (BP) is a chronic, autoimmune blistering disease that has concerning morbidity and mortality rates. Recently, several studies have focused on eosinophils due to their significant role in the pathogenesis of BP, considering that they are ubiquitous in the serum, tissue, and blister f luids of patients with BP. With this context, precision therapy that targets mediators of eosinophil activity could be a possible novel therapeutic strategy. Interleukin (IL)-5 is crucial for B-cell maturation, which consequently results in immuno- globulin production, and promotes eosinophil differentiation, proliferation, and activation. To our best knowledge, reslizumab has not yet been reported to treat BP. Herein, we report a case of steroid- and omalizumab-resistant BP treated successfully using reslizumab. Our data suggest that IL-5 could be a novel specific biologic target within the entire immuno- pathogenesis of BP, and reslizumab would be a novel therapeutic modality.
Abstract
Bullous pemphigoid (BP) is a chronic, autoimmune blistering disease that has concerning morbidity and mortality rates. Recently, several studies have focused on eosinophils due to their significant role in the pathogenesis of BP, considering that they are ubiquitous in the serum, tissue, and blister f luids of patients with BP. With this context, precision therapy that targets mediators of eosinophil activity could be a possible novel therapeutic strategy. Interleukin (IL)-5 is crucial for B-cell maturation, which consequently results in immuno- globulin production, and promotes eosinophil differentiation, proliferation, and activation. To our best knowledge, reslizumab has not yet been reported to treat BP. Herein, we report a case of steroid- and omalizumab-resistant BP treated successfully using reslizumab. Our data suggest that IL-5 could be a novel specific biologic target within the entire immuno- pathogenesis of BP, and reslizumab would be a novel therapeutic modality.
참고문헌 (19)
- Simon D, "Eosinophils as putative therapeutic targets in bullous pemphigoid", Exp Dermatol, 26, pp.1187~1192 (2017)
- Amber KT, "The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease", Front Med(Lausanne), 5, pp.201~ (2018)
- Kremer N, "Rituximab and omalizumab for the treatment of bullous pemphigoid : a systematic review of the literature", Am J Clin Dermatol, 20, pp.209~216 (2019)
- Kouro T, "IL-5-and eosinophil-mediated inflammation : from discovery to therapy", Int Immunol, 21, pp.1303~1309 (2009)
- Takatsu K, "Interleukin 5 and B cell differentiation", Cytokine Growth Factor Rev, 9, pp.25~35 (1998)
- Tominaga A, "Role of the interleukin 5 receptor system in hematopoiesis : molecular basis for overlapping function of cytokines", Bioessays, 14, pp.527~533 (1992)
- D’Auria L, "IL-5 levels in the serum and blister fluid of patients with bullous pemphigoid : correlations with eosinophil cationic protein, RANTES, IgE and disease severity", Arch Dermatol Res, 290, pp.25~27 (1998)
- Liu Y, "Factors associated with the activity and severity of bullous pemphigoid : a review", Ann Med, 52, pp.55~62 (2020)
- Wakugawa M, "Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid : correlation with tissue eosinophilia", Br J Dermatol, 143, pp.112~116 (2000)
- Deeks ED, "Reslizumab in eosinophilic asthma : a review", Drugs, 77, pp.777~784 (2017)
- 박세현, "Circulating Eosinophil and Neutrophil Counts Correlate with Disease Severity in Bullous Pemphigoid", Annals of Dermatology, 30(5), pp.544~549 (2018), 대한피부과학회
- Gore Karaali M, "Tissue eosinophil levels as a marker of disease severity in bullous pemphigoid", Australas J Dermatol, 62, pp.e236~e241 (2021)
- Teraki Y, "Skin-homing interleukin-4 and-13-producing cells contribute to bullous pemphigoid : remission of disease is associated with increased frequency of interleukin-10-producing cells", J Invest Dermatol, 117, pp.1097~1102 (2001)
- Abdat R, "Dupilumab as a novel therapy for bullous pemphigoid : a multicenter case series", J Am Acad Dermatol, 83, pp.46~52 (2020)
- Cozzani E, "Immunoglobulin E and bullous pemphigoid", Eur J Dermatol, 28, pp.440~448 (2018)
- Freire PC, "IgE autoreactivity in bullous pemphigoid : eosinophils and mast cells as major targets of pathogenic immune reactants", Br J Dermatol, 177, pp.1644~1653 (2017)
- Fang H, "The autoimmune skin disease bullous pemphigoid : the role of mast cells in autoantibodyinduced tissue injury", Front Immunol, 9, pp.407~ (2018)
- Messingham KN, "Human eosinophils express the high affinity IgE receptor, FcεRI, in bullous pemphigoid", PLoS One, 9, pp.e107725~ (2014)
- Simon D, "Mepolizumab failed to affect bullous pemphigoid : a randomized, placebo-controlled, double-blind phase 2 pilot study", Allergy, 75, pp.669~672 (2020)